---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-000853"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:15:09.311445+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# EyePoint appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

## Summary
- Appointed Michael C. Pine as Chief Corporate Development and Strategy Officer, effective January 10, 2022.
- Annual base salary of $420,000; sign-on bonus of $108,000 payable in two equal tranches.
- Granted options to purchase 100,000 shares at $12.62/share, vesting 25% on first anniversary then monthly through fourth year.
- Mr. Pine brings over 20 years of pharma experience, most recently SVP at Medexus Pharmaceuticals.
- Inducement award under Nasdaq Listing Rule 5635(c)(4); subject to forfeiture provisions.

## SEC filing metadata
- accession: 0001564590-22-000853
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000156459022000853/0001564590-22-000853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000156459022000853/eypt-8k_20220110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-000853
- JSON: https://secwatch.observer/filing/0001564590-22-000853.json
- Plain text: https://secwatch.observer/filing/0001564590-22-000853.txt

## Key facts
- Executive change
  Michael C. Pine was appointed as Chief Corporate Development and Strategy Officer at EyePoint, Inc..
  - Action: appointed
  - Role: Chief Corporate Development and Strategy Officer
  source text: On January 10, 2022 (the “ Start Date ”), EyePoint Pharmaceuticals, Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Michael C. Pine, age 46, as the Company’s Chief Corporate Development and Strategy Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000156459022000853/0001564590-22-000853-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.